Trial Profile
A Phase 1 Study of Single Agent Pexidartinib in Asian Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary)
- Indications Adenoid cystic carcinoma; Bladder cancer; Chordoma; Giant cell tumours; Liver cancer; Malignant fibrous histiocytoma; Neuroendocrine tumours; Pelvic cancer; Renal cell carcinoma; Salivary gland cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 25 Jun 2021 Status changed from active, no longer recruiting to completed.
- 15 Oct 2020 Planned End Date changed from 1 Aug 2020 to 1 Aug 2021.
- 02 Mar 2019 Results published in the Investigational New Drugs